Penetration of HIV-1 protease inhibitors into CSF and semen.
Taylor
S
S
PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham, UK.
Pereira
A
A
D018791:CD4 Lymphocyte Count; D002219:Carbamates / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D017320:HIV Protease Inhibitors / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D008297:Male; D019888:Nelfinavir / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D019438:Ritonavir / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D019258:Saquinavir / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D012661:Semen / Q000187:drug effects* / Q000821:virology; D013449:Sulfonamides / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics; D019562:Viral Load
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; C095108:amprenavir; D019888:Nelfinavir; D019258:Saquinavir; D019438:Ritonavir